United States

Horizon Pharma PLC (HZNP.O)

HZNP.O on Nasdaq

26 Sep 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Select another date:

Mon, Sep 12 2016

BRIEF-Raptor Pharma says to pay Horizon Pharma termination fee of $30 mln if deal terminated

* In connection with termination of merger, Raptor will be required to pay to Horizon Pharma a termination fee of $30 million Source text for Eikon: [http://bit.ly/2celZU2] Further company coverage:

BRIEF-Horizon pharma Q2 diluted earnings per share $0.09

* Horizon Pharma Plc announces second-quarter 2016 financial results

Exclusive: Horizon Pharma explores potential stake sale - sources

Specialty pharmaceutical company Horizon Pharma Plc has hired Bank of America Corp to help it explore selling a significant equity stake to an investor that would bolster its balance sheet, people familiar with the matter said on Monday.

BRIEF-Horizon Pharma to buy rights to interferon gamma-1b from Boehringer Ingelheim

* Says anticipates a reduction to 2016 adjusted ebitda of approximately $10 million versus prior guidance

BRIEF-Horizon Pharma says settles patent litigation with Teligent

* Horizon Pharma Plc announces settlement of Pennsaid(r) (diclofenac sodium topical solution) 2 pct w/w patent litigation with Teligent Inc.

BRIEF-Horizon Pharma says received notice of allowance from U.S. Patent Office

* Horizon Pharma announces u.s. Patent and trademark office issuance of additional notice of allowance with claims covering Krystexxa (pegloticase) Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

BRIEF-Horizon Pharma Plc says settled Pennsaid(R) patent litigation

* Horizon Pharma Plc announces settlement of Pennsaid(R) (diclofenac sodium topical solution) 2% w/w patent litigation with Amneal Pharmaceuticals Llc

BRIEF-Depomed, Horizon Pharma Plc, Horizon Pharma Inc agree to settle claims

* On April 22, 2016, co,each of Horizon Pharma Plc and Horizon Pharma, Inc. mutually agreed to settle their respective claims against other

BRIEF-Horizon Pharma Plc confirms FY 2016 net sales, adj. EBITDA guidance

* Confirming its full-year 2016 net sales guidance of $1.025 to $1.050 billion - SEC filing

BRIEF-Horizon Pharma says not interested in revisiting interest in Depomed

* Says "not interested in revisiting our previous interest in Depomed" Further company coverage:

Select another date: